850 related articles for article (PubMed ID: 29031784)
1. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
Yao X; Xia F; Tang W; Xiao C; Yang M; Zhou B
J Ethnopharmacol; 2018 Feb; 212():208-215. PubMed ID: 29031784
[TBL] [Abstract][Full Text] [Related]
2. Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-Based Proteomic Analysis of Hugan Qingzhi and Its Protective Properties against Free Fatty Acid-Induced L02 Hepatocyte Injury.
Xia F; Yao X; Tang W; Xiao C; Yang M; Zhou B
Front Pharmacol; 2017; 8():99. PubMed ID: 28293193
[TBL] [Abstract][Full Text] [Related]
3. Hugan Qingzhi tablets attenuates endoplasmic reticulum stress in nonalcoholic fatty liver disease rats by regulating PERK and ATF6 pathways.
Yang M; Yao X; Xia F; Xiang S; Tang W; Zhou B
BMC Complement Med Ther; 2024 Jan; 24(1):36. PubMed ID: 38216941
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.
Tang W; Yao X; Xia F; Yang M; Chen Z; Zhou B; Liu Q
Oxid Med Cell Longev; 2018; 2018():7261619. PubMed ID: 30671174
[TBL] [Abstract][Full Text] [Related]
5. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
Yin J; Luo Y; Deng H; Qin S; Tang W; Zeng L; Zhou B
J Ethnopharmacol; 2014 May; 154(1):229-39. PubMed ID: 24735863
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].
Yao XR; Xia F; Tang WJ; Zhou BJ
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):56-62. PubMed ID: 28109099
[TBL] [Abstract][Full Text] [Related]
7. Hugan Qingzhi medication ameliorates free fatty acid-induced L02 hepatocyte endoplasmic reticulum stress by regulating the activation of PKC-δ.
Yang M; Chen Z; Xiang S; Xia F; Tang W; Yao X; Zhou B
BMC Complement Med Ther; 2020 Dec; 20(1):377. PubMed ID: 33308192
[TBL] [Abstract][Full Text] [Related]
8. Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease.
Tang W; Zeng L; Yin J; Yao Y; Feng L; Yao X; Sun X; Zhou B
Evid Based Complement Alternat Med; 2015; 2015():810369. PubMed ID: 26146507
[TBL] [Abstract][Full Text] [Related]
9. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.
You L; Wang T; Li W; Zhang J; Zheng C; Zheng Y; Li S; Shang Z; Lin J; Wang F; Qian Y; Zhou Z; Kong X; Gao Y; Sun X
J Ethnopharmacol; 2024 Jul; 329():118165. PubMed ID: 38588984
[TBL] [Abstract][Full Text] [Related]
10. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
11. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
12. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
Zheng C; Nie H; Pan M; Fan W; Pi D; Liang Z; Liu D; Wang F; Yang Q; Zhang Y
J Ethnopharmacol; 2024 Jan; 318(Pt A):116967. PubMed ID: 37506783
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats.
Wang Y; Li JY; Han M; Wang WL; Li YZ
Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978
[TBL] [Abstract][Full Text] [Related]
14. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
15. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
[TBL] [Abstract][Full Text] [Related]
16. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
[TBL] [Abstract][Full Text] [Related]
17. Comparative proteomic analysis using 2DE-LC-MS/MS reveals the mechanism of Fuzhuan brick tea extract against hepatic fat accumulation in rats with nonalcoholic fatty liver disease.
Liu Z; Lin Y; Zhang S; Wang D; Liang Q; Luo G
Electrophoresis; 2015 Sep; 36(17):2002-16. PubMed ID: 26036873
[TBL] [Abstract][Full Text] [Related]
18. Shenge Formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1.
Shang Z; Gao Y; Xue Y; Zhang C; Qiu J; Qian Y; Fang M; Zhang X; Sun X; Kong X; Gao Y
Phytomedicine; 2024 Jan; 123():155183. PubMed ID: 37992491
[TBL] [Abstract][Full Text] [Related]
19. Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease.
Zhang X; Zhang J; Zhou Z; Xiong P; Cheng L; Ma J; Wen Y; Shen T; He X; Wang L; Zhang Y; Xiao C
J Ethnopharmacol; 2024 May; 325():117828. PubMed ID: 38325669
[TBL] [Abstract][Full Text] [Related]
20. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
Chen M; Xing J; Pan D; Peng X; Gao P
Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
